ResearcherID - CLICK HERE Scientific Journal Impact Factor (SJIF-2020) - CLICK HERE

DIRECT ACTING ANTIVIRALS (DAA) IN CHRONIC HEPATITIS C INFECTION WITH LIVER CIRRHOSIS

Dr. Maryam Basharat, Dr. Mina Mishal, Dr. Mujahid Abbas

Chronic hepatitis C virus (HCV) infection could ultimately trigger liver cirrhosis (LC), an ailment corresponding by getting a high risk of liver failure and hepatocellular carcinoma. Despite the fact that interferon (IFN)-based therapy has produced considerable advantages to the handling of HCV-infected patients, this particular treatment has restrictions for LC patients with regards to qualification, tolerability, reasonably minimal and higher rates of sustained virological response (SVR), and serious adverse events. The development of Direct-acting antiviral (DAA) therapy could customize the consequence of HCV infection through the vast majority of patients. Regrettably, the chronic nature of HCV infection means that many patients requiring direct acting antiviral (DAA) therapy have already developed compensated cirrhosis. As mentioned, treatment with recently evolved direct-acting antiviral agents (DAAs) can overcome these limitations in IFN-based therapy. Recently, in the phase three trials have revealed that DAA therapy produced high SVR rates (more than 90% for genotype 1; 80% to 90% for genotype 2; 60% to 70% for genotype 3) for compensated LC patients, with high tolerability and relatively low rates of serious adverse events. Furthermore, trials have suggested that DAA therapy can be used for the treatment of decompensated LC patients as well as pre-transplant and post-transplant LC patients. In this article, we review the current status of DAA therapy for HCV-related LC patients. Keywords: Liver cirrhosis; Hepatitis C virus; Direct-acting antiviral agents.

FULL TEXT